Owlet, Inc. (NYSE:OWLT) Q4 2022 Earnings Call Transcript

Kurt Workman: Yes, we’ve made substantial progress towards our international applications, there is two. There’s the U.K. application and the CE applications, which are similar in nature, but one will allow us to gain clearance in the U.K. and the other will allow us to gain EU medical device certification. Both submissions will be filed with the notified body in the second quarter of this year. And we also continue to maintain our MDSAP and ISO 1345 certifications for that international compliance. And so our vision is to have medical device status globally, which we believe will better empower parents in every region to deliver the best care possible for their baby.

Mike Cavanaugh: Great. Thanks. And operator, I think we may have another question in the queue.

Operator: Yes. We have a follow-up from Charles Rhyee. Your line is now open.

Charles Rhyee: Thanks. I was going to ask about the submission. So you guys answered it. So appreciate it. Thanks, guys.

Kurt Workman: Thanks, Charles.

Operator: Thank you for your question. There are no additional questions waiting at this time. So I’ll turn it back to Kurt for any closing remarks.

Kurt Workman: Yes. I just want to take a minute to thank everybody who has been so supportive of the business through the past year and getting back online with Dream Sock, getting our FDA submissions and really grateful for the team that has dug in to accomplish a lot of work in a very short period of time to get Owlet in a position to be focusing on getting to profitability this year and getting FDA clearances, which we believe are going to provide a lot of future growth for the business and also will help improve the safety and health of a lot of babies and help a lot of families. So thank you so much for your time today, and we’ll continue to work hard.

Operator: That concludes the conference call. Thank you for your participation. You may now disconnect your lines.